^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Cervical Cancer

    Related cancers:
    1d
    Targeting KIF23 inhibits cell proliferation and primary chemoresistance in cervical cancer by inactivating the MYH9/MCM2/PCNA pathway. (PubMed, Clin Transl Med)
    Cisplatin treatment induces KIF23 expression in a concentration- and time-dependent manner. KIF23 recruits USP7, which removes the K48-linked ubiquitin chain of MYH9, thereby stabilising MYH9 and facilitating its nuclear transport. MYH9 recruits USP15, thereby stabilising MCM2, which, in turn, regulates the G1/S phase transition by binding to PCNA. Targeting the KIF23/MYH9/MCM2/PCNA axis sensitises cervical cancer cells to cisplatin.
    Journal
    |
    MYH9 (Myosin Heavy Chain 9) • PCNA (Proliferating cell nuclear antigen) • KIF23 (Kinesin Family Member 23) • MCM2 (Minichromosome maintenance complex component 2) • USP7 (Ubiquitin Specific Peptidase 7)
    |
    cisplatin
    2d
    Comparative Analysis of Homologous Recombination Repair Status Across Gynecologic and Breast Cancers in Chinese Populations. (PubMed, Curr Cancer Drug Targets)
    The mutational patterns affecting homologous recombination repair differ across gynecologic and breast cancers. Further research into cancer-specific HRD mechanisms is warranted.
    Journal • Tumor mutational burden • BRCA Biomarker • PARP Biomarker
    |
    TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • MSI (Microsatellite instability) • HRD (Homologous Recombination Deficiency) • JAK2 (Janus kinase 2) • PALB2 (Partner and localizer of BRCA2) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • BRCA (Breast cancer early onset) • EPHA5 (EPH Receptor A5)
    |
    TP53 mutation • BRCA2 mutation • BRCA1 mutation • PIK3CA mutation • HRD • PALB2 mutation • BRCA mutation
    2d
    Baicalein induces cervical cancer apoptosis via PTEN/PI3K/AKT pathway modulation. (PubMed, Pak J Pharm Sci)
    Our findings reveal that baicalein enhances PTEN tumor suppressor function to inhibit PI3K/AKT signaling, and suggest that combining natural compounds with tumor suppressor restoration represents a promising therapeutic strategy for cervical cancer.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • PDK1 (Pyruvate Dehydrogenase Kinase 1)
    4d
    MYH9 Promotes the Proliferation and Progression of Squamous Cervical Cancer Cells. (PubMed, Recent Pat Anticancer Drug Discov)
    MYH9 acts as an oncogenic gene in SCC, which promotes the carcinogenesis and progression of SCC cells via EMT signaling, and it may serve as a valuable patent for targeted treatment biomarker of SCC.
    Journal
    |
    CCND1 (Cyclin D1) • MYH9 (Myosin Heavy Chain 9) • JUN (Jun proto-oncogene)
    4d
    Effectiveness and Impact of the Lived Experience Cancer Awareness Campaign on Screening Participation (clinicaltrials.gov)
    P=N/A, N=1120, Active, not recruiting, International Agency for Research on Cancer | Enrolling by invitation --> Active, not recruiting | Trial completion date: Dec 2025 --> May 2026 | Trial primary completion date: Sep 2025 --> Jan 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    4d
    HPV-Vac-S: Impact of HPV Vaccination on Prevention of Cervical HPV Infection in Sikkim, India (clinicaltrials.gov)
    P=N/A, N=5500, Recruiting, International Agency for Research on Cancer | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Jun 2025 --> Oct 2026
    Trial completion date • Trial primary completion date
    4d
    Unique pattern of endometrial invasion in gastric-type adenocarcinoma of the uterine cervix: a report of two cases. (PubMed, Int Cancer Conf J)
    The reduction in CD8-positive TILs density around invasive GAS glands indicates an immunologically "cold" tumor microenvironment that may contribute to treatment resistance. The present results provide novel insights into the pathology of GAS that may inform more effective diagnostic approaches and therapeutic strategies for this aggressive malignancy.
    Journal
    |
    CLDN18 (Claudin 18) • CD8 (cluster of differentiation 8)
    5d
    Negative HPV Test Results on Infinity/GeneXpert® With the Presence of a Late Amplification Signal: What Does This Mean ? (PaPCR) (clinicaltrials.gov)
    P=N/A, N=45, Completed, University Hospital, Brest | Recruiting --> Completed | Trial completion date: Aug 2025 --> Jan 2026 | Trial primary completion date: Aug 2025 --> Apr 2025
    Trial completion • Trial completion date • Trial primary completion date
    5d
    Targeting the AKT/mTOR axis: pectolinarigenin induces autophagy and apoptosis in human cervical cancer cells. (PubMed, Front Pharmacol)
    These findings highlighted the potential of PEC as a promising natural therapeutic agent for CC, paving the way for new treatment strategies. Further comprehensive research is warranted to fully explore PEC's therapeutic capabilities and to develop innovative anti-cancer therapies.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3)
    5d
    Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer. (PubMed, Cancer Res)
    Mapping of the impact of chemoradiation on cellular interactions in cervical cancer reveals how treatment reshapes the tumor microenvironment and highlights targets for developing future immunotherapeutic approaches. See related commentary by Klopp, p. 1540.
    Journal
    |
    TP53 (Tumor protein P53)
    |
    TP53 wild-type
    6d
    Multicenter Evaluation of 2 Vaginal Self-Collection Devices for HPV Testing. (PubMed, J Low Genit Tract Dis)
    This study is among the first US multicenter evaluations comparing 2 self-collection devices on the same molecular platform. It demonstrated that the clinical sensitivity of the Alinity m HR HPV assay for cervical disease detection (≥ CIN2) using both SCS and EB self-collected vaginal specimens is comparable to that in CC specimens. Overall, HPV agreement rates were consistent with those reported for other validated self-collected devices.
    Journal
    |
    ALINITY m HR HPV ASSAY
    6d
    Endocervical gastric-type AIS: a rare histologic finding that further supports the hypothesis of a pyloric-type metaplastic origin. (PubMed, Histopathology)
    This case supports a possible link between gAIS and pyloric-type gastric metaplasia, underscoring the importance of accurate recognition in HPV-independent cervical lesions.
    Journal
    |
    TP53 (Tumor protein P53) • CDX2 (Caudal Type Homeobox 2) • PAX8 (Paired box 8)
    |
    TP53 mutation